Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy

Hashimoto,Ryoji; Kanda,Mitsuro; Takami,Hideki; Shimizu,Dai; Oya,Hisaharu; Hibino,Soki; Okamura,Yukiyasu; Yamada,Suguru; Fujii,Tsutomu; Nakayama,Goro; Sugimoto,Hiroyuki; Koike,Masahiko; Nomoto,Shuji; Fujiwara,Michitaka; Kodera,Yasuhiro

doi:10.3892/ol.2014.2823

Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy

Authors:
- Ryoji Hashimoto
- Mitsuro Kanda
- Hideki Takami
- Dai Shimizu
- Hisaharu Oya
- Soki Hibino
- Yukiyasu Okamura
- Suguru Yamada
- Tsutomu Fujii
- Goro Nakayama
- Hiroyuki Sugimoto
- Masahiko Koike
- Shuji Nomoto
- Michitaka Fujiwara
- Yasuhiro Kodera
View Affiliations

Affiliations: Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan
Published online on: December 23, 2014 https://doi.org/10.3892/ol.2014.2823
Pages: 1201-1206

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the most common cause of cancer‑related mortality globally. Since the prognosis of advanced HCC patients is extremely poor, the development of novel molecular targets for diagnosis and therapy is urgently required. In the present study, the expression of the melanoma‑associated antigen‑D2 (MAGE‑D2) gene was investigated to determine whether it affects the malignant phenotype of HCC and thus, may serve as a marker of prognosis. Therefore, the expression of MAGE‑D2 mRNA and MAGE‑D2 protein in nine HCC cell lines and 151 pairs of surgical tissues was analyzed. mRNA expression levels were analyzed using reverse transcription‑quantitative polymerase chain reaction and immunohistochemistry was used to compare the clinicopathological parameters of the tumors. A significant difference in the level of MAGE‑D2 expression was observed between the normal liver and chronic hepatitis tissues, however, no significant differences were identified among the levels of the chronic hepatitis, cirrhosis and HCC tissues. The expression patterns of the MAGE‑D2 protein were consistent with those of its mRNA. The expression levels of MAGE‑D2 mRNA in 66 of 151 (44%) patients were higher in the HCC tissues compared with the corresponding non‑cancerous tissues. In addition, the disease‑specific survival time was significantly shorter for patients with higher levels of MAGE‑D2 mRNA expression. Multivariate analysis identified increased expression of MAGE‑D2 mRNA as an independent prognostic factor for disease‑specific survival (hazard ratio, 2.65; 95% confidence interval, 1.43‑4.98; P=0.002). However, increased expression levels of MAGE‑D2 mRNA were not significantly associated with other clinicopathological parameters, including extrahepatic recurrence. These results indicated that MAGE‑D2 mRNA affects tumor progression and may serve as a prognostic indicator following curative resection. In addition, MAGE‑D2 may provide a target for the therapy of HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138. 2013.PubMed/NCBI
3	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
4	Mínguez B and Lachenmayer A: Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers. 31:181–190. 2011. View Article : Google Scholar : PubMed/NCBI
5	Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
6	Llovet JM, Ricci S, Mazzaferro V, et al: SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
7	El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 127(5 Suppl 1): S27–S34. 2004. View Article : Google Scholar : PubMed/NCBI
8	Herath NI, Leggett BA and MacDonald GA: Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol. 21:15–21. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kanda M, Nomoto S, Nishikawa Y, et al: Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol. 98:190–196. 2008. View Article : Google Scholar : PubMed/NCBI
10	Miki D, Ochi H, Hayes CN, Aikata H and Chayama K: Hepatocellular carcinoma: towards personalized medicine. Cancer Sci. 103:846–850. 2012. View Article : Google Scholar : PubMed/NCBI
11	Villanueva A, Newell P, Chiang DY, Friedman SL and Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kanda M, Nomoto S, Okamura Y, et al: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 35:477–483. 2009.PubMed/NCBI
13	Sang M, Wang L, Ding C, et al: Melanoma-associated antigen genes-an update. Cancer Lett. 302:85–90. 2011. View Article : Google Scholar
14	Chang CC, Campoli M, Luo W, et al: Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Ann NY Acad Sci. 1028:340–350. 2004. View Article : Google Scholar
15	Barker PA and Salehi A: The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res. 67:705–712. 2002. View Article : Google Scholar : PubMed/NCBI
16	Xiao J and Chen HS: Biological functions of melanoma-associated antigens. World J Gastroenterol. 10:1849–1853. 2004.PubMed/NCBI
17	Langnaese K, Kloos DU, Wehnert M, Seidel B and Wieacker P: Expression pattern and further characterization of human MAGED2 and identification of rodent orthologues. Cytogenet Cell Genet. 94:233–240. 2001. View Article : Google Scholar
18	Oya H, Kanda M, Takami H, et al: Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Dis Esophagus. Oct 21–2013.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
19	Takami H, Kanda M, Oya H, et al: Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol. 108:557–562. 2013. View Article : Google Scholar : PubMed/NCBI
20	Sobin LH, Gospodarowicz MK and Wittekind C: International Union Against Cancer. TNM classification of malignant tumors. 7th edition. Wiley-Blackwell; New York, NY: 2009
21	Kanda M, Nomoto S, Okamura Y, et al: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI
22	Arzumanyan A, Reis HM and Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
23	Khare S, Zhang Q and Ibdah JA: Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol. 19:5439–5445. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hernandez-Gea V, Toffanin S, Friedman SL and Llovet JM: Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 144:512–527. 2013. View Article : Google Scholar : PubMed/NCBI
25	Kanda M, Nomoto S, Oya H, et al: Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol. 44:44–52. 2014.
26	Bertrand M, Huijbers I, Chomez P and De Backer O: Comparative expression analysis of the MAGED genes during embryogenesis and brain development. Dev Dyn. 230:325–334. 2004. View Article : Google Scholar : PubMed/NCBI
27	Harper R, Xu C, Di P, et al: Identification of a novel MAGE D2 antisense RNA transcript in human tissues. Biochem Biophys Res Commun. 324:199–204. 2004. View Article : Google Scholar : PubMed/NCBI
28	Kidd M, Modlin IM, Mane SM, et al: The role of genetic markers - NAP1L1, MAGE-D2, and MTA1 - in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol. 13:253–262. 2006. View Article : Google Scholar : PubMed/NCBI
29	Papageorgio C, Brachmann R, Zeng J, et al: MAGED2: a novel p53-dissociator. Int J Oncol. 31:1205–1211. 2007.PubMed/NCBI
30	Kidd M, Modlin IM, Mane SM, et al: Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer. 106:1480–1488. 2006. View Article : Google Scholar : PubMed/NCBI
31	Li M, Lin YM, Hasegawa S, et al: Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol. 24:305–312. 2004.PubMed/NCBI
32	Tseng HY, Chen LH, Ye Y, et al: The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells. Carcinogenesis. 33:1871–1881. 2012. View Article : Google Scholar : PubMed/NCBI